Latest purchasing details: How patients purchase ixazomib

Ixazomib, sold under the brand name Ninlaro, is a drug used to treat multiple myeloma (MM, a cancer of the white blood cells) that can be used in combination with other drugs. It is taken orally in capsule form. Common side effects include diarrhea, constipation, and low platelet count. Like the older bortezomib (which can only be administered by injection), it has orphan drug status in the United States and Europe as a second-generation proteasome inhibitor and is a boronic acid derivative. The drug was developed by Takeda. In the United States, it has been approved since November 2015, and in the European Union since November 2016. In vitro studies have shown that ixazomib can induce apoptosis in multiple myeloma cells that are sensitive or resistant to other conventional therapies. Ixazomib induces tumor growth inhibition in mouse xenograft models.

The original drug of ixazomib has been launched in China and is included in Class B medical insurance. The price of a common capsule preparation may be more than 10,000 yuan per box, which is relatively expensive. This drug may be sold in domestic hospitals or pharmacies, but it must be obtained with a doctor's prescription. The price of each box of the original ixazomib drug sold overseas is more than 10,000 US dollars (the price may fluctuate due to exchange rates). Ixazomib Generic drugs are also produced and sold overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 4mg*3 tablets produced by a Laos pharmaceutical factory may be less than 1,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap. For information on overseas drug prices and information, consult Yaode Medical Consultants.